3 ASX biotech shares rated as buys in 2022

We hear the expert opinion of analysts covering the space.

| More on:
a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX biotech shares were a mixed bag in 2021. Several of the majors came in behind their benchmarks whilst many smaller players outshone the pack.

The sector has been the benefactor of long-term tailwinds in diagnostics and demand for novel treatment solutions this year. However, the momentum has been pared back across the board.

For instance, the S&P/ASX 300 Pharmaceuticals & Biotechnology Index (AXPBKD) has spiked from its lows this month after collapsing hard in early December. Yet, zooming out a little, it is down 8% off previous highs and now trading at October 2021 levels.

As the impacts of COVID-19 begin to wind back, the growth outlook for the ASX biotech space is one to look out for over the coming 12 months, according to several experts covering the space.

Here's what stocks analysts are recommending for ASX biotech shares in 2022.

Telix Pharmaceuticals Ltd (ASX: TLX)

Shares in oncology company Telix recently passed their previous 12-month highs over recent weeks and, at the time of writing, are now trading for $7.85 apiece.

Telix's novel imaging platform for prostate cancer, Illuccix, has been in focus lately. News surrounding Illucix has seen investors piling into Telix to secure a spot in the company's growth engine for 2022.

Most recently, the company advised the US Food & Drug Administration (FDA) had approved the technology for use as a diagnostic imaging platform for prostate cancer.

Aside from this, the company also recently advised its Illucix platform was awarded marketing authorisation application (MAA) in Europe. It now expects European approval for registration status no later than 23 March 2022.

All of this regulatory momentum has analysts updating their outlook on Telix's growth potential into the new year.

Indeed, the team at Wilsons recently raised its valuation by 53% to $10.35 and reckons Telix is a buy at its current prices.

Meanwhile, just before Christmas, analysts at Bell Potter also upgraded their valuation on Telix by another 16%. They feel the company's shares are worth $9.65 apiece whereas both Jarden and Jefferies also reckon Telix is a buy, valuing the company at $8.50 and $7 respectively.

CSL Ltd (ASX: CSL)

Shares in biotech giant CSL were on a rollercoaster ride in 2021 and showed a wide spread in pricing across the year to date.

For instance, the $140 billion company (by market capitalisation) traded as low at $246 and closed as high as $317 in that time — a 29% spread in price action.

Now, with CSL's acquisition of Vifor Pharma for US$11.7 billion confirmed and due to settle in the coming months, several experts reckon its share price is set to spike in 2022. They rate the company as a buy.

Certainly, the team at investment bank Citi reckons the acquisition to be "[approximately] 9% accretive to NPTA (NPAT before acquisition-related amortization)" – a proxy for cash flow.

When factoring in the non-cash item of amortization, the transaction is expected to be "modestly accretive" to earnings per share (EPS). CSL also raised $6.3 billion in capital to finance the transaction, the largest primary equity raise in ASX history.

Citi recently upgraded its recommendation on CSL shares to a buy with a bullish $340 per share price target, implying an upside potential of 16% at the time of writing.

Morgans is equally as bullish and just recently raised its price target by 3% to $334 per share. The broker says that investors' worries about the deal are "misplaced as this deal looks as unique as CSL itself, allowing access to a defensible specialty product portfolio with strong market positions and growth opportunities, far from a 'typical' pharma transaction".

Morgans reckons CSL is a buy in 2022 alongside Jarden, Jefferies and Macquarie — just to name a few.

Immutep Ltd (ASX: IMM)

Shares in Aussie biotech Immutep have also been on the back end of some wide-reaching volatility this year. They're now trading at 49.5 cents a share.

However, this is a substantial plunge from the company's 12-month highs of around 70 cents a share earlier in the year.

Immmutep's novel LAG-3 solution has been the major focus for investors and analysts this year, although the company has also seen growth in other areas of its pipeline in 2021.

For instance, the company recently advised it has signed a Manufacturing Service Agreement
(MSA) with contract manufacturer Northway Biotech, to manufacture IMP761 ahead of clinical testing.

IMP761 is one of Immutep's preclinical candidates for autoimmune diseases. It is classed as an immunosuppressive agonist antibody to LAG-3.

Under the agreement, Northway will manufacture IMP761 in large scale bioreactors. After completion of the required preclinical developments, the material produced will be used for Immutep's clinical trials of IMP761.

Momentum like this has the team at Jefferies interested, with the firm recently initiating coverage with a buy and a $1 per share price target.

Wilsons is also bullish on the company. It notes how LAG-3 has changed the narrative on cancer investigation and treatment for the better which, it believes, the market could be overlooking.

The broker values Immutep at 91 cents with a buy recommendation. Meanwhile, Bell Potter also rates the company as a "speculative buy" at $1 per share.

All in all, the average price target of $1.12 on Immutep's share price implies an upside potential of 124% into 2022 should these brokers' forecasts come to fruition.

The author has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 ASX healthcare shares surging on big news

The ASX healthcare sector is higher on Tuesday and these stocks are among the strongest performers.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The pros and cons of buying CSL shares right now

It’s an interesting time to consider this healthcare giant.

Read more »

Vanadium Resources share price person riding rocket indicating share price increase
Healthcare Shares

Why did this ASX biotech stock explode 52% higher on Monday?

Shareholders of this stock were smiling today. What happened?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is everyone talking about ResMed shares?

It’s been a good year for ResMed shareholders. Let’s find out why.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »